FilingReader Intelligence

Huahai Pharmaceutical secures dual drug registration certificates

July 11, 2025 at 08:49 AM UTCBy FilingReader AI

Zhejiang Huahai Pharmaceutical obtained drug registration certificates for Metoprolol Succinate Extended-Release Tablets and Nicardipine Hydrochloride Injection.

The Metoprolol tablets, for hypertension, angina, and chronic heart failure, required 17.04m yuan in domestic research and development. The domestic market is projected to reach 3.066bn yuan in 2024.

The Nicardipine injection, for emergency hypertension management, cost 4.98m yuan to develop. Its domestic market is estimated at 632m yuan in 2024.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SSE:600521Shanghai Stock Exchange
Pharmaceuticals

News Alerts

Get instant email alerts when Zhejiang Huahai Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →